Multiple myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells causing a wide variety of complications leading to organ dysfunction and eventually death. It is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow.
In the United States, the lifetime risk for MM is 1 in 143 (0.7%). The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies.
The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.
#DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers.
Have a Copy our Newsletter-- https://www.delveinsight.com/whitepaper-newsletter/multiple-myeloma-newsletter
Know More About What's Covered:
· Indication overview
· Signs, symptoms, and diagnosis
· Epidemiological trends
· Treatment approaches
· Unmet needs
· Market insights
· Key Companies
· Clinical trials
· R&D in the field
· Top conferences
· Support from International organizations
· Collaborations and deals in the domain
Have a Copy our Newsletter-- https://www.delveinsight.com/whitepaper-newsletter/multiple-myeloma-newsletter
#raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #multiplemyeloma #readerscommunity #readinglist #newsletterdesign
Comments
Post a Comment